XBIT
XBiotech Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.20
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 4.0M |
| Cost of Revenue | 332.0K | 1.7M | — | — | 651.0K |
| Gross Profit | (332.0K) | (1.7M) | — | — | 3.4M |
| Operating Expenses | |||||
| R&D Expense | 40.9M | 47.4M | 37.8M | 32.8M | 31.5M |
| SG&A Expense | 7.3M | 8.3M | 4.7M | 4.7M | 6.3M |
| General & Admin Expense | 7.3M | 8.3M | 4.7M | 4.7M | 6.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (332.0K) | (1.7M) | — | — | — |
| Total Operating Expenses | 47.9M | 54.0M | 42.5M | 37.5M | 37.8M |
| Cost and Expenses | 48.2M | 55.7M | 42.5M | 37.5M | 38.5M |
| Operating Income (EBIT) | (48.2M) | (55.7M) | (42.5M) | (37.5M) | (34.5M) |
| Non-Operating | |||||
| Interest Income | 4.4M | 5.7M | 9.8M | 10.4M | 3.8M |
| Interest Expense | — | 88.0K | 807.0K | — | — |
| Net Interest Income | 4.4M | 5.6M | 9.0M | 10.4M | 3.8M |
| Other Non-Op Income/Expense | 3.4M | 10.4M | 3.9M | 13.2M | 902.0K |
| Non-Operating Income (excl Interest) | (5.3M) | (10.5M) | (4.7M) | (13.2M) | (902.0K) |
| EBT (Pre-Tax Income) | (44.9M) | (45.3M) | (38.6M) | (24.3M) | (33.6M) |
| Income Tax Expense | 273.0K | 235.0K | (32.0K) | 244.0K | (688.0K) |
| Bottom Line | |||||
| Net Income | (45.1M) | (45.5M) | (38.5M) | (24.6M) | (32.9M) |
| Earnings from Cont. Ops | (45.1M) | (45.5M) | (38.5M) | (24.6M) | (32.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (45.1M) | (45.5M) | (38.5M) | (24.6M) | (32.9M) |
| Per Share | |||||
| Basic EPS | ($1.48) | ($1.49) | ($1.26) | ($0.81) | ($1.08) |
| Diluted EPS | ($1.48) | ($1.49) | ($1.26) | ($0.81) | ($1.08) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.13 |
| Shares | |||||
| Basic Shares Outstanding | 30.5M | 30.5M | 30.5M | 30.3M | 30.4M |
| Diluted Shares Outstanding | 30.5M | 30.5M | 30.5M | 30.4M | 30.4M |
| Profitability Metrics | |||||
| EBITDA | (41.8M) | (43.5M) | (36.0M) | (22.6M) | (31.0M) |
| D&A | 1.1M | 1.7M | 1.7M | 1.7M | 2.6M |
| EBIT | (42.9M) | (45.2M) | (37.8M) | (24.3M) | (33.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026